Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wilson, Wyndham H, Prof, O'Connor, Owen A, Prof, Czuczman, Myron S, Prof, LaCasce, Ann S, MD, Gerecitano, John F, MD, Leonard, John P, Prof, Tulpule, Anil, MD, Dunleavy, Kieron, MD, Xiong, Hao, PhD, Chiu, Yi-Lin, PhD, Cui, Yue, PhD, Busman, Todd, MS, Elmore, Steven W, PhD, Rosenberg, Saul H, PhD, Krivoshik, Andrew P, MD, Enschede, Sari H, MD, Humerickhouse, Rod A, MD
Published in The lancet oncology (01.12.2010)
Published in The lancet oncology (01.12.2010)
Get full text
Journal Article